AssetMark Inc
NBIX icon

AssetMark Inc’s Neurocrine Biosciences NBIX Stock Holding History

AssetMark Inc’s Portfolio NBIX Stock Details NBIX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q3 		$2.18M Sell
15,392
-1,022
-6% -$164K ﹤0.01% 927
2026
Q2 		$2.77M Sell
16,414
-863
-5% -$128K ﹤0.01% 878
2026
Q1 		$2.28M Sell
17,277
-2,044
-11% -$271K ﹤0.01% 857
2025
Q4 		$2.74M Sell
19,321
-915
-5% -$133K 0.01% 781
2025
Q3 		$2.84M Sell
20,236
-765
-4% -$104K 0.01% 738
2025
Q2 		$2.64M Buy
21,001
+2,045
+11% +$235K 0.01% 714
2025
Q1 		$2.1M Sell
18,956
-958
-5% -$121K 0.01% 709
2024
Q4 		$2.72M Buy
19,914
+1,591
+9% +$197K 0.01% 641
2024
Q3 		$2.11M Buy
18,323
+1,753
+11% +$240K 0.01% 642
2024
Q2 		$2.28M Buy
16,570
+4,460
+37% +$612K 0.01% 580
2024
Q1 		$1.67M Sell
12,110
-24,845
-67% -$3.39M 0.01% 619
2023
Q4 		$4.87M Buy
36,955
+8,678
+31% +$999K 0.02% 376
2023
Q3 		$3.18M Buy
28,277
+4,350
+18% +$458K 0.01% 424
2023
Q2 		$2.26M Buy
23,927
+4,151
+21% +$406K 0.01% 455
2023
Q1 		$2M Buy
19,776
+1,903
+11% +$198K 0.01% 451
2022
Q4 		$2.13M Buy
17,873
+1,471
+9% +$172K 0.01% 423
2022
Q3 		$1.74M Buy
16,402
+2,929
+22% +$297K 0.01% 407
2022
Q2 		$1.31M Buy
13,473
+4,317
+47% +$398K 0.01% 435
2022
Q1 		$858K Buy
9,156
+4,093
+81% +$347K ﹤0.01% 502
2021
Q4 		$431K Buy
5,063
+3,585
+243% +$330K ﹤0.01% 568
2021
Q3 		$142K Buy
+1,478
New +$140K ﹤0.01% 612
2019
Q3 		– Sell
-12
Closed -$1K – 1382
2019
Q2 		$1K Buy
12
+2
+20% +$164 ﹤0.01% 1252
2019
Q1 		$1K Sell
10
-18
-64% -$1.5K ﹤0.01% 1261
2018
Q4 		$2K Buy
+28
New +$2.68K ﹤0.01% 1224
2018
Q1 		– Sell
-20
Closed -$2K – 1777
2017
Q4 		$2K Buy
20
+15
+300% +$1.02K ﹤0.01% 1463
2017
Q3 		$0 Buy
+5
New +$264 ﹤0.01% 1568
2016
Q1 		– Sell
-15
Closed -$1K – 1336
2015
Q4 		$1K Buy
+15
New +$762 ﹤0.01% 1233

Other funds holding NBIX

Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $551B AUM 33.95% 1-Year Est. Return
Swedbank
Swedbank Stockholm, Sweden $118B AUM 40.52% 1-Year Est. Return
Ninety One (UK)
Ninety One (UK) London, United Kingdom $45.5B AUM 15.2% 1-Year Est. Return
KBC Group
KBC Group Brussels, Belgium $47.9B AUM 37.61% 1-Year Est. Return
Pictet Asset Management
Pictet Asset Management Carouge, Switzerland $106B AUM 32.76% 1-Year Est. Return
Seizert Capital Partners
Seizert Capital Partners Birmingham, Michigan $2.3B AUM 16.06% 1-Year Est. Return
DekaBank Deutsche Girozentrale
DekaBank Deutsche Girozentrale Frankfurt, Germany $87.8B AUM 20.94% 1-Year Est. Return
Candriam SCA
Candriam SCA Strassen, Luxembourg, Luxembourg $22.5B AUM 50.38% 1-Year Est. Return
Allspring Global Investments
Allspring Global Investments Charlotte, North Carolina $64.1B AUM 28.9% 1-Year Est. Return
Citigroup
Citigroup New York $308B AUM 40.94% 1-Year Est. Return

AssetMark Inc's NBIX Position: Q3 2026 in Review

AssetMark Inc reduced its Neurocrine Biosciences (NBIX) stake by 6.2% in Q3 2026, selling an estimated $164K and leaving 15,392 shares worth $2.18M. The position accounts for ﹤0.01% of the portfolio, ranked #927.

AssetMark Inc first reported a position in NBIX in Q4 2015 and has held it in 27 quarters since. The position peaked at $4.87M in Q4 2023. 312 funds tracked by Wall St. Rank hold NBIX as of Q3 2026.

  • AssetMark Inc held 15,392 shares of Neurocrine Biosciences worth $2.18M as of Q3 2026.
  • AssetMark Inc sold 1,022 Neurocrine Biosciences shares in Q3 2026, an estimated $164K.
  • Neurocrine Biosciences made up ﹤0.01% of AssetMark Inc's portfolio in Q3 2026, its #927 holding.
  • AssetMark Inc first reported a position in Neurocrine Biosciences in Q4 2015 and has held it in 27 quarters since.
  • AssetMark Inc's Neurocrine Biosciences position peaked at $4.87M in Q4 2023.
  • 312 funds tracked by Wall St. Rank held Neurocrine Biosciences as of Q3 2026.

Based on AssetMark Inc's 13F filing for Q3 2026, filed 21 Oct 2026.